End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia by Hoque, Shamia et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
1-1-2020 
End of an era of administering erythropoiesis stimulating agents 
among Veterans Administration cancer patients with 
chemotherapy-induced anemia 
Shamia Hoque 
University of South Carolina - Columbia 
Brian J. Chen 
University of South Carolina - Columbia 
Martin W. Schoen 
Saint Louis University 
Kenneth R. Carson 
Washington University School of Medicine in St. Louis 
Jesse Keller 
Washington University School of Medicine in St. Louis 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Recommended Citation 
Hoque, Shamia; Chen, Brian J.; Schoen, Martin W.; Carson, Kenneth R.; Keller, Jesse; Witherspoon, Bartlett 
J.; Knopf, Kevin B.; Yang, Y Tony; Schooley, Benjamin; Nabhan, Chadi; Sartor, Oliver; Yarnold, Paul R.; Ray, 
Paul; Bobolts, Laura; Hrushesky, William J.; Dickson, Michael; and Bennett, Charles L., ,"End of an era of 
administering erythropoiesis stimulating agents among Veterans Administration cancer patients with 
chemotherapy-induced anemia." PLoS One.,. . (2020). 
https://digitalcommons.wustl.edu/open_access_pubs/9254 
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been 
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. 
For more information, please contact engeszer@wustl.edu. 
Authors 
Shamia Hoque, Brian J. Chen, Martin W. Schoen, Kenneth R. Carson, Jesse Keller, Bartlett J. Witherspoon, 
Kevin B. Knopf, Y Tony Yang, Benjamin Schooley, Chadi Nabhan, Oliver Sartor, Paul R. Yarnold, Paul Ray, 
Laura Bobolts, William J. Hrushesky, Michael Dickson, and Charles L. Bennett 
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/9254 
RESEARCH ARTICLE
End of an era of administering erythropoiesis
stimulating agents among Veterans
Administration cancer patients with
chemotherapy-induced anemia
Shamia HoqueID
1‡*, Brian J. Chen2‡, Martin W. SchoenID3, Kenneth R. Carson4,
Jesse Keller4, Bartlett J. Witherspoon5, Kevin B. Knopf6, Y. Tony Yang7,
Benjamin Schooley8, Chadi Nabhan6, Oliver Sartor9, Paul R. Yarnold5,6, Paul Ray6,
Laura Bobolts10,11, William J. Hrushesky4,5,6, Michael Dickson6, Charles L. Bennett6
1 Department of Civil and Environmental Engineering, College of Engineering and Computing, University of
South Carolina, Columbia, South Carolina, United States of America, 2 Arnold School of Public Health,
University of South Carolina, Columbia, South Carolina, United States of America, 3 Department of Medicine,
Saint Louis University School of Medicine, Saint Louis, Missouri, United States of America, 4 The
Washington University School of Medicine and the Saint Louis VA Medical Center, St. Louis, Missouri, United
States of America, 5 Medical University of South Carolina, Charleston, South Carolina, United States of
America, 6 College of Pharmacy, University of South Carolina, Columbia, South Carolina, United States of
America, 7 George Washington University, Washington, DC, United States of America, 8 Department of
Integrated Information Technology, College of Engineering and Computing, University of South Carolina,
Columbia, South Carolina, United States of America, 9 Tulane University School of Medicine, New Orleans,
Louisiana, United States of America, 10 Oncology Analytics, Plantation, Florida, United States of America,
11 College of Pharmacy, Nova Southeastern University, Fort Lauderdale, Florida, United States of America
‡ These authors share first authorship on this work.
* hoques@cec.sc.edu
Abstract
Erythropoisis stimulating agent (ESA) use was addressed in Food and Drug Administration
(FDA) Oncology Drug Advisory Committee (ODAC) meetings between 2004 and 2008. FDA
safety-focused regulatory actions occurred in 2007 and 2008. In 2007, black box warnings
advised of early death and venous thromboembolism (VTE) risks with ESAs in oncology. In
2010, a Risk Evaluation Strategies (REMS) was initiated, with cancer patient consent that
mortality and VTE risks were noted with ESAs. We report warnings and REMS impacts on
ESA utilization among Veterans Administration (VA) cancer patients with chemotherapy-
induced anemia (CIA). Data were from Veterans Affairs database (2003–2012). Epoetin
and darbepoetin use were primary outcomes. Segmented linear regression was used to
estimate changes in ESA use levels and trends, clinical appropriateness, and adverse
events (VTEs) among chemotherapy-treated cancer patients. To estimate changes in level
of drug prescription rate after policy actions, model-specific indicator variables as covariates
based on specific actions were included. ESA use fell by 95% and 90% from 2005, for epoe-
tin and darbepoetin, from 22% and 11%, respectively, to 1% and 1%, respectively, among
cancer patients with CIA, respectively (p<0.01). Following REMS in 2010, mean hematocrit
levels at ESA initiation decreased from 30% to 21% (p<0.01). Black box warnings preceded
decreased ESA use among VA cancer patients with CIA. REMS was followed by reduced
hematocrit levels at ESA initiation. Our findings contrast with privately- insured and Medicaid
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insured cancer patient data on chemotherapy-induced anemia where ESA use decreased
to 3% to 7% by 2010–2012. By 2012, the era of ESA administration to VA to cancer patients
had ended but the warnings remain relevant and significant. In 2019, oncology/hematology
national guidelines (ASCO/ASH) recommend that cancer patients with chemotherapy-
induced anemia should receive ESAs or red blood cell transfusions after risk-benefit
evaluation.
Introduction
Prescription drugs treat diseases and improve patients’ quality of life. However, no drug is
completely safe [1,2]. Food and Drug Administration (FDA) balances risks and benefits by
mandating manufacturer disclosure via warnings on product labels. Since 2007, FDA started
requiring manufacturers to implement safety efforts, including consent via Risk Evaluation
and Monitoring Strategies (REMS) [3–7]. A meta-analysis that public health advisories often
led to decreased drug use and fleeting increases in drug monitoring [8]. No analyses report on
use changes following REMS-mandated consent processes. Public health advisories impact
incident, but not prevalent use [9,10]. Boxed warnings are associated with utilization reduc-
tions, but substitution between classes occurs [11–17]. Empirical evidence shows that boxed
warnings have mixed results in leading to lower drug utilization. There is a need to identify
factors associated with “rapid and sustained responses to risk communications.” [8]
We assessed impacts of boxed warnings and REMS on use and adverse outcomes of two
drugs (epoetin and darbepoetin)- Erythropoiesis Stimulating Agents (ESAs). These drugs are
associated with mortality and venous thromboembolism (VTE) risks when administered to
cancer patients [18–28]. ESAs are approved for chemotherapy-induced anemias (CIAs) to
minimize transfusions [19,29] Initial trials found a 36% reduction in red blood cell transfu-
sions [18]. Meta-analytic studies found elevated thrombosis risk (7.5% vs. 4.9%) [19], increased
mortality risk (Hazard Ratio = 1.10, 95% CI [1.01, 1.20]) [19] and Hazard Ratio = 1.17, 95% CI
[1.06, 1.3]) [20] and decreased overall survival when cancer patients received ESAs (Hazard
Ratio = 1.06, 95% CI [1.0, 1.12]) [20].
Discovery of adverse events led to boxed warnings in 2007 limiting ESA use to cancer
patients with CIA receiving chemotherapy with palliative intent. FDA, concerned that label
changes were insufficient, mandated in 2010 that ESAs have Risk Evaluation and Mitigation
Strategies (REMS) [29,30]. REMS, enhanced regulatory actions [31], included medication
guides; communication plans, elements to assure safe use, and plans for monitoring compli-
ance [32].
ESA risk communication chronologies offers opportunities to study safety warnings in
diverse settings as shown in Table 1. Past research in non-VA systems found ESA warnings
had limited impact [8,20,33–42]. Distinctions between VA and non-VA systems exist [43]. In
non-VA settings, drug companies rebate physician offices for administered intravenous drugs
[44]. Differences between insurers’ reimbursed prices of intravenously infused biologics and
physicians’ rebated prices represents incentives to prescribe drugs [44–46]. For VA physicians,
financial incentives are lacking. We studied ESAs epoetin and darbepoetin separately, an
important distinction [47] because price mark-ups, reimbursement policies, and intensity of
pharmaceutical detailing differ between ESAs.
Changing prescribing behavior is essential. Little evidence evaluates warning effectiveness
and FDA-mandated REMS in reducing serious adverse events [48–51]. Impacts of warnings
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and REMS on utilization of ESAs and on adverse outcomes were assessed. Prescribing changes
are particularly important in the setting of ESAs, where 2019 guidelines from the American
Society of Clinical Oncology/the American Society of Hematology state that “depending on
clinical circumstances, ESAs may be offered to patients with chemotherapy-associated anemia
whose cancer treatment is not curative in intent and whose hemoglobin has declined to< 10
grams/deciliter [55]. Patterns of care data from South Carolina Medicaid showed that in 2010,
3% and 7% of cancer patients with chemotherapy-induced anemia received epoetin and darbe-
poetin, respectively [47]. It is not known what the frequency of use of epoetin and darbepoetin
in the Veterans Administration system was in 2010- an observation that would have implica-
tions for current practice. In particular, if epoetin and darbepoetin use in 2010 in the VA set-
ting were negligible, then this would imply that in the VA setting, clinicians strongly viewed
red blood cell transfusion or allowing patients to have lower baseline hemoglobin levels as pre-




Data were from VA Integrated Service Networks (VISNs), using the VINCI (VA informatics
and computing infrastructure) research environment. The Veterans Affairs Central Cancer
Registry (VACCR) includes information on cancer diagnosis date, cancer site, stage of dis-
ease, and age, gender, race and ethnicity. VA Pharmacy Benefits files included national
drug codes (NDC), prescription date, quantity, VA station number, and physician ID num-
bers. All of the patient information was anonymized during the data analysis stage. The
study was reviewed by the full Institutional Review Board of the WJB Dorn Veterans
Administration Medical Center (IRBNet Number: 1007797). The IRB waived the require-
ment of informed consent.
Eligible chemotherapy-treated cancer patient identification. Non-small cell lung can-
cer, colorectal cancers, and breast cancer were focused on. These cancers differ from each
other in patient profiles, clinical characteristics, treatment, and prognoses. All patients had a
diagnosis of cancer between 2005 and 2012. Eligible patients were at least 18 years old and
younger than 90 years of age. Patients were tracked from chemotherapy administration for as
long as chemotherapy was continually administered or death.
Chemotherapy administration. Chemotherapy administration was determined from
inpatient/outpatient encounter records, pharmacy records, carrier claims and registry data
between the date of the diagnosis (for registry cases) or first cancer claim (other cases) and six
months later.
Table 1. Chronicle of regulatory actions and safety information related to ESAs.
1989–2002 2003–2006 2007 2010 2017
In 1989, Epogen (epoetin) was
approved by the FDA for
anemic renal failure patients. In
1993, Procrit (epoetin) was
approved for anemic cancer
under chemotherapy patients.
In 2002, Aranesp (darbepoetin)
was approved for both anemic
renal failure and anemic cancer
patients under chemotherapy.
A majority of evidence from
RCTs on increased risks of
tumor progression, blood
clotting, stroke, heart attacks,
and/or mortality associated
with the use of ESAs began to
emerge.
In March, the FDA issued a
black box warning on ESAs
used for renal failure and some
types of cancer. Immediately
thereafter, CMS issued new
coverage and reimbursement
policies for ESAs.
In March, the FDA issued the




to assure safe use, and a
monitoring plan.
In April, the FDA removed




showing appropriate use of
ESAs.
https://doi.org/10.1371/journal.pone.0234541.t001
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Outcomes
ESA treatment use and transfusion. For each course of chemotherapy administration, it
was determined whether either epoetin or darbepoetin was dispensed. Use of ESA (epoetin,
NDC (national drug code) 55513-126-xx and darbepoetin NDC code 55513-021-xx) was ascer-
tained. Blood transfusion was identified from outpatient encounter data (CPT code 36430–
36460).
VTE occurrence and mortality. A VTE event required an ICD-9 code in the first or sec-
ond position on claims related files (the first claim), as per the method of Hershman et al in
evaluating ESAs in the SEER-Medicare dataset [52]. For each chemotherapy course, the last
epoetin or darbepoetin administration was identified and created an indicator variable equal
to 1 for those with a VTE within 60 days after last ESA administration. Two indicators,
vte60epo and vte60darbe, were created. If a patient died within courses of chemotherapy
administration, an event observable based on date of death in vital statistics files, an indicator
variable “died” was created equal to 1.
Chronic conditions, hematocrit and cancer stage. Comorbid disease was based on the
Klabunde adaptation of Charlson indices [53]. Medicare inpatient/outpatient codes were
searched for ICD-9 diagnostic codes and chronic conditions files. Each condition was
weighted. Patients were assigned scores based on the Klabunde-Charlson index given comor-
bid conditions during chemotherapy administration periods. Hematocrit values were mea-
sured as percentages based on the average hematocrit values for three-months prior to ESA
initiation. Cancer stage was designated as the closest in time prior to ESA initiation.
Control variables
Sociodemographics. Patient sociodemographic information included age, gender, race/
ethnicity, and marital status. Age was measured from date of birth to date of cancer diagnosis
or first claim for cancer. Age was categorized into five-year intervals. Race/ethnicity was cate-
gorized as African American, Hispanic, non-Hispanic white, and all others. Patients were
identified as married/not.
Geographic variables. All data sets except SEER-Medicare provided patient residence at
zip code levels. To ensure consistency, the geographic variable was defined at the county level.
VA station ID variables. These variables served as fixed effects in segmented regression
analyses. These fixed effects absorb time-invariant unobserved characteristics in our longitudi-
nal dataset, such as organizational incentives to prescribe drugs.
Statistical analyses: Segmented regression analyses
We used segmented linear regression to estimate changes in ESA use changes on levels and
trends, clinical appropriateness, and adverse events (VTEs) among chemotherapy-treated can-
cer patients. The analysis was conducted separately for epoetin only, darbepoetin only, and for
both epoetin/darbepoetin. These analyses accounted for baseline level and drug use trends
while estimating changes in level and trend resulting from policy interventions. The models
included a variable reflecting the number of intervals after the first quarter (X1(t)). To estimate
changes in level of drug prescription rate after policy actions, we included model-specific indi-
cator variables as covariates based on specific actions were included.
We used slope and trend coefficients to help estimate mean differences between ESA rates
of use between the intervention (the observed rate) and times without intervention (the
expected rates) for specific quarters. The quarters were based on policy changes and other
interventions of interest. The following quarters were evaluated: For ESAs, the first quarter
after the FDA-disseminated public health advisories and the concomitant manufacturer-issued
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boxed warning on the ESA products (April to June 2007), the last quarter after the public
health advisories and the box warnings and before initiation of the REMS program (October
to December 2009), and the last quarter after REMS (October to December 2016). To assess
model assumptions, we tested for residual autocorrelation at various lags. We used, partial
autocorrelation and inverse autocorrelation plots to visually assess for residual autocorrelation.
The regression had the following specification:
yijt ¼ b0 þ b1 � countert þ b2 � post boxed warningt þ b3 � quarters since boxed warningt þ b4
� post REMSt þ b5 � quarters since REMSt þ βlXijt þ aj þ εijt ð1Þ
The subscript i denotes a unique patient, j, a unique VA station, and t, the time (in quarter)
when chemotherapy began. Y is the various outcomes, including ESA use, adverse outcomes
(VTE or death), control variables (i.e., Charlson index, hematocrit values, anemia diagnosis,
and cancer stage). Counter is a variable that counted the number of quarters since the begin-
ning study period (2005 quarter 1). It represented the slope of the trend in the outcome vari-
able before any risk communications. Post boxed warning identified the level change in the
outcome variable after warnings were announced in 2007 quarter 1. Quarters since the public
health advisories and the boxed warning is a second counter variable that is 0 in all quarters
prior to 2007 quarter 1 and begins counting at 1 through each passing quarter from 2007 quar-
ter 1. The variable captured slope changes from pre-public health notifications and boxed
warning periods to post-public health advisories and warning periods. Likewise, post REMS
and quarters since REMS respectively captured the level change and the slope change (from the
pre-REMS period) in outcome variables. X, a vector of control variables, includes age, race,
type of cancer, cancer stage, Charlson index, anemia diagnosis, and hematocrit. However,
when one of these control variables was the dependent variable, it was removed as a control
variable. Finally, α (VA station fixed effects) controlled for time-invariant VA station-specific
heterogeneity, and ε was a random error term.
P-values for coefficient estimates for individual datasets and 95% confidence intervals are
reported. All p-values were two-sided with a threshold of 0.05. All analyses were performed
using Stata Version 15, with data assembly and cleaning in SQL and SAS.
Results
A total of 91,233 courses of chemotherapy administration was identified, some individuals
received more than one chemotherapy course (Table 2). Only 8.5% of cancer patients with
concomitant chemotherapy received at least one dose of epoetin, and the corresponding per-
centage for darbepoetin is 3.8%. At the height of ESA use, which occurred before the 2008
Warning, 23.2% and 11% of chemotherapy patients were respectively administered epoetin
and darbepoetin (Figs 1 and 2).
In the overall sample, mean patient age was 67 years, of whom 6.5% were female. Our
cohort is 64.9% White, and 12.3% African American. Lung cancer represented the largest per-
cent at 59.2%, followed by colon cancer, and breast cancer at 25.4% and 5%. Patients had
advanced cancer- 74.2% at stages 2, 3, and 4. Average Charlson index scores were 5.499, 24.2%
of patients had anemia, and 5.5% of patients required blood transfusions. Overall, 28.6% of
patients died.
Cancer patients administered chemotherapy and epoetin or darbepoetin were sicker than
chemotherapy only populations, with greater proportions of cancer stages III or IV (49.4% and
51.1%), higher Charlson scores (6.31 and 6.32), greater anemia rates (65.9% and 63.1%) and
transfusion (21.4% and 23.4%), and mortality rates (43.3% and 41.4%) respectively for epoetin
and darbepoetin users. ESA use dropped after the Boxed Warning, but was falling even prior
PLOS ONE End of an era of administering erythropoiesis stimulating agents
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to this (Fig 1A and 1B). VTE rates and deaths did not inflect at the point of boxed warnings.
Clinical indicators coincided with practices counseled by boxed warnings (Figs 3 and 4).
Multivariate regression analyses confirmed three trends: ESA use, both for epoetin and dar-
bepoetin, fell consistently throughout the entire study period (2005–2012), with additional
level changes occurring around the time of the boxed warnings; there is no evidence that the
warnings reduced adverse events (VTEs and death); and following boxed warnings, VA physi-
cians administered ESAs to patients with higher cancer stage.
The most consistent results are that the boxed warnings were associated with most dramatic
reductions in use of epoetin and darbepoetin (S1 Table). The negative coefficients on pre-
Boxed Warning trends show that ESA use was already falling prior to the warnings. There
were statistically significant discontinuities in ESA use, with reductions of 4.3% (p<0.01) and
3.1% (p<0.01) in likelihood of epoetin and darbepoetin prescription, respectively. Coefficients
on changes in trend after the boxed warning, level changes after REMS, and trend changes
after REMS are all positive and significant.
Because the cohort consists of all cancer patients on chemotherapy (S2 Table), the remain-
ing regression results are interpreted as temporal trends in outcomes for VA cancer patients
on chemotherapy. These results suggest no temporal changes in VTE or mortality risks. There
was an increase of 3.7% in the likelihood of having an anemia diagnosis after REMS and
increases in average Charlson scores by 0.16 (p<0.01) and 0.32 (p<0.01) after the boxed
Table 2. Summary statistics.
All chemotherapy patients Chemotherapy and epoetin Chemotherapy and darbepoetin
Mean St. Dev. Mean St. Dev. Mean St. Dev.
N 73,703 7,051 3,209
Age 67.168 10.076 66.828 9.784 66.677 9.740
Female (%) 0.065 0.049 0.049
Married (%) 0.460 0.490 0.487
White (%) 0.649 0.592 0.569
Black (%) 0.123 0.136 0.161
Asian (%) 0.002 0.001 0.001
Hispanic (%) 0.008 0.012 0.004
Other race (%) 0.219 0.259 0.265
Epoetin (%) 0.085 1.000 1.000
Darbepoetin (%) 0.038 0.451 1.000
Chemotherapy (%) 1.000 1.000 1.000
Duration (months) 0.924 1.413 0.390 0.794 0.372 0.757
Lung cancer (%) 0.592 0.664 0.682
Breast cancer (%) 0.050 0.028 0.028
Colon cancer (%) 0.254 0.171 0.155
Lymphoma (%) 0.114 0.143 0.140
Cancer stage 1 (%) 0.258 0.146 0.138
Cancer stage 2 (%) 0.375 0.360 0.351
Cancer stages 3 & 4 (%) 0.367 0.494 0.511
Charlson Index 5.499 6.306 6.321
Anemia Diagnosis (%) 0.242 0.659 0.631
Transfusion (%) 0.055 0.214 0.234
Died (%) 0.286 0.433 0.414
Hematocrit 36.883 5.778 33.543 5.484 33.560 5.344
https://doi.org/10.1371/journal.pone.0234541.t002
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Fig 1. (a) VA cancer patients on epoetin and (b) VA Cancer patients on darbepoetin.
https://doi.org/10.1371/journal.pone.0234541.g001
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warning and REMS. The likelihood of being diagnosed as cancer stage 1 increased by 1.8%
post Boxed Warning. S2 and S3 Tables focus on trends in outcome variables conditional
respectively on epoetin and darbepoetin prescription, respectively. As in regressions using the
entire cohort, our results show that neither mortality nor VTE rates fell over time. The most
significant result is that hematocrit values at the time of ESA initiation dropped after REMS
were initiated (p<0.01 for epoetin and darbepoetin).
Discussion
Our main findings are ESA use fell consistently throughout the study period, for both epoetin
and darbepoetin, but the boxed warnings created an additional reduction in ESA utilization;
adverse events (VTEs and death) did not decrease following boxed warnings or REMS; VA
physicians responded differentially to the REMS versus the boxed warnings by decreasing the
initial hematocrit level when initiating ESAs; and as of 2010, administration of epoetin or dar-
bepoetin for treatment of chemotherapy-induced anemia was negligible.
Fig 2. Percent of VA cancer patients within 60 days (a) VTE event after epoetin, (b) VTE event after darbepoetin, (c) death after chemotherapy—epoetin and (d) death
after chemotherapy—darbepoetin.
https://doi.org/10.1371/journal.pone.0234541.g002
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Our results differ from literature where physicians are reimbursed for administering drugs
intravenously in clinical settings. The divergence is interesting, given that all studies assess
impacts of boxed warnings on the same drugs in different contexts–the VA system, Medicaid,
Medicare, and commercial health insurance. Oure results suggest that financial considerations
do not appear to affect how VA physicians react to safety warnings.
In a prior study of the South Carolina Medicaid program where financial considerations
are relevant, Noxon et al found differential utilization patterns for epoetin versus darbepoetin
following warnings and safety actions [47]. For epoetin, utilization decreased steadily between
2002 and 2010, where darbepoetin use increased between 2003 and 2007 and then decreased
thereafter. Per-patient dosing of darbepoetin, but not epoetin, increased between 2003 and
2010, and monthly per-patient epoetin costs decreased 3% while per-patients costs of darbe-
poetin increased 30% between 2003 and 2010. Noxon et al reported that in 2010, epoetin and
darbepoetin were administer to 3% and 7%, respectively, or cancer patients with chemother-
apy-induced anemia [54]. In contrast, in the VA system in 2010, 1% of cancer patients with
Fig 3. Percent of VA cancer patients with anemia diagnosis (a) epoetin, (b) darbepoetin, and average hematocrit levels of VA cancer patients (a) epoetin, (b)
darbepoetin.
https://doi.org/10.1371/journal.pone.0234541.g003
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Fig 4. Average cancer state of VA cancer patients for (a) epoetin and (b) darbepoetin.
https://doi.org/10.1371/journal.pone.0234541.g004
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chemotherapy-induced anemia received epoetin or darbepoetin, respectively- strongly indicat-
ing the “end of the ESA era” at least in the VA system.
Among Medicare providers where financial considerations for individual providers are rel-
evant, Bian et al showed that compared with a control group, ESA use started declining sharply
after warnings were issued, concomitant with Center for Medicare and Medicaid Services
(CMS) institution of a National Coverage Decision mandating non-payment for ESAs if
hematocrit levels were > 30%, whereas ESA use trends remained similar with the control
before warnings [55]. VTE trends were stable. The study found that the boxed warnings/CMS
decision were associated with a 20.2-percentage-point reduction in likelihood of ESAs being
used in the cancer setting, but were not associated with VTE reductions.
Our study contradicts with results from a study by Schoen et al that uses the IMS LifeLink™
Health Plan Claims Database, which is composed of commercial health plan information [56].
They found that odds of receiving epoetin decreased after risk communications and REMS,
but initially increased for darbepoetin after box warnings were disseminated. They found that
the odds of receiving a high darbepoetin dose increased from 2001 to 2012, whereas odds of
receiving a high epoetin dose decreased after REMS, suggesting that physicians increased per-
patient darbepoetin dosing as the prevalence of darbepoetin use declined. Also, epoetin and
darbepoetin rates of use in 2012 for chemotherapy-induced anemia were 3.1% and 2.6%,
respectively, while in the VA, these rates of use were 1% and 1%, respectively.
Our study findings can be compared to those reported for Ontario, Canada for ESA use
among cancer patients with chemotherapy-induced anemia between 2007 and 2009 and for
VA use between 2002 and 2008 [57,58]. Tarlov et al. and our study identifies the beginning of
marked decrease in ESA use for chemotherapy-induced anemia beginning in 2005, following
publications of poorer survival and high venous thromboembolism rates among ESA-treated
cancer patients [57]. Their data is limited by not following ESA use beyond 2009 prior to initi-
ating the ESA REMS program. Weir et al report that in Ontario, ESA use for chemotherapy
induced anemia did not begin to decline until Canada Health and the FDA disseminated Black
Box warnings about ESA use in these settings in 2007 [58]. In Canada, ESA use appeared to be
influenced by national policies and regulatory decisions, whereas VA use of ESAs is strongly
influenced by physician practice patterns, which changed markedly following publication of
two large randomized controlled trials with ESAs in 2003.
While other incentive-driven contexts showed divergent utilization patterns between epoe-
tin and darbepoetin, this was not seen herein. Yet ESA suppliers likely marketed their drugs
with different degrees of aggressiveness. Amgen, the supplier of darbepoetin, settled civil liti-
gation for allegations of over-promotion and over-marketing of darbepoetin (for $610 million
to the Department of Justice and $72 million to 48 state Medicaid programs) and pled guilty to
related criminal charges (paying $160 million- the largest federal fines/settlements in U.S. his-
tory related to a biologic product)) [47]. VA physicians, who are paid a fixed salary, were less
susceptible to pharmaceutical detailing.
Conclusion
ESA use fell in the VA system from 2005, even prior to the 2007 FDA boxed warnings for epoe-
tin and darbepoetin, a finding that was initially reported by Tarlov et al. when evaluating VA
use of ESAs between 2002 and 2009 [57]. Boxed warnings served as additional nudges to
reduce utilization following safety-related concerns identified in clinical trials in 2003 and con-
form to clinical suggestions in warnings, such as to advise ESA use only among cancer patients
treated for palliative intent. Possibly due in part to the low ESA use 2010, we did not find sig-
nificant reductions in adverse outcomes because variance around these outcomes was great.
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We also found that the mean hematocrit level decreased following the 2010 REMS—indicating
that patient consent may have been associated with patient and physician reluctance to receive
ESAs at higher hematocrit levels. Our results suggest that boxed warnings had intended effects
in the VA, contrary to other insurance contexts where financial incentives to prescribe profit-
able injectable drugs may distort impacts of risk communications. REMS provided additional
disincentives against ESA use that were not noted following the boxed warnings.
Taken in context with other studies by Bian et al. [55] for Medicare, Weir et al. [58] for
Ontario, Canada, Noxon et al. [54] for South Carolina Medicaid, the results suggest that safety
actions may have differential reactions across insurance types. ESA use appeared to have fallen
earlier and was more consistent for epoetin and darbepoetin in the VA than in systems with
financial incentives. This finding can help policymakers tailor messaging and supporting poli-
cies and/or regulatory action to specific insurance contexts. Policymakers may consider mea-
sures such as tort law changes (to raise “cost” of not heeding FDA risk communications), drug
reimbursement policy reform and legislative reform on pharmaceutical marketing and detail-
ing (to lower overprescribing), including a more nuanced interpretation of First Amendment
free speech rights for off-label marketing.
A final important conclusion is that in the VA system, the era of administering epoetin or
darbepoetin to cancer patients with chemotherapy-induced anemia appeared to end in 2012- a
finding that is different from that reported among cancer patients covered by private health
insurance or Medicaid health insurance.
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